Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v2.4.0.8
Commitments and Contingencies (Details) (USD $)
9 Months Ended
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member] | Phase I Clinical Trial of a licensed product [Member]
 
Summary of milestone payment  
Milestones payments $ 750,000
Abbott Biotherapeutics Corp [Member] | Phase II Clinical Trial of a licensed product [Member]
 
Summary of milestone payment  
Milestones payments 750,000
Abbott Biotherapeutics Corp [Member] | Phase III Clinical Trial of a licensed product [Member]
 
Summary of milestone payment  
Milestones payments 1,500,000
Abbott Biotherapeutics Corp [Member] | Biological License Application filing with U.S. FDA [Member]
 
Summary of milestone payment  
Milestones payments 1,750,000
Abbott Biotherapeutics Corp [Member] | First Commercial Sale [Member]
 
Summary of milestone payment  
Milestones payments 1,500,000
Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member]
 
Summary of milestone payment  
Milestones payments 1,500,000
Memorial Sloan Kettering Cancer Center [Member] | New Drug Application [Member]
 
Summary of milestone payment  
Milestones payments 750,000
Memorial Sloan Kettering Cancer Center [Member] | Receipt of Regulatory Approval From U.S. FDA [Member]
 
Summary of milestone payment  
Milestones payments $ 1,750,000